Results 131 to 140 of about 392,479 (342)

The clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation: the LIFT prospective RCT

open access: yesEfficacy and Mechanism Evaluation
Background Long-term surviving liver transplant recipients can spontaneously develop operational tolerance, which allows them to completely discontinue their immunosuppression, but we lack validated tools to predict the likelihood of rejection following ...
Julien Vionnet   +22 more
doaj   +1 more source

Targeting immunosuppression by Tregs with monoclonal antibodies against GARP [PDF]

open access: gold, 2016
Stéphanie Liénart   +3 more
openalex   +1 more source

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

open access: yesAdvanced Science, EarlyView.
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu   +34 more
wiley   +1 more source

Polymyxin B-immobilized fiber hemoperfusion therapy improves sepsis-related immunosuppression [PDF]

open access: gold, 2014
Akifumi Kimura   +10 more
openalex   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

open access: yesAdvanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia   +14 more
wiley   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu   +10 more
wiley   +1 more source

Advocating for the recognition of underlying immunosuppression in critical illness

open access: yesEClinicalMedicine
Summary: Immunosuppression, characterised by impaired immune function, significantly influences infection risk and ICU admissions in critically ill patients.
Ignacio Martin-Loeches   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy